Liver disease

MiNA Therapeutics has dosed the first patient in a global Phase II clinical trial (OUTREACH-2) of MTL-CEBPA in combination with second line standard of care sorafenib (a tyrosine kinase inhibitor (TKI)) in advanced hepatocellular carcinoma (HCC or liver cancer).  What is OUTREACH-2?  OUTREACH-2 is a multi-centre, open-label, randomised study of MTL-CEBPA in combination with sorafenib, compared to sorafenib […]

Dompé Farmaceutici has entered a strategic collaboration with and investment in Engitix as part of Engitix’s $54m Series A financing to support identification of new treatments against fibrosis and liver-associated solid tumours.  The agreement   Dompé will provide direct access to facilities, resources and expertise including its Exscalate structure-based drug design platform which can design new molecules following the rules of rational drug design to obtain […]

In a clinical trial, Mount Sinai scientists gave immunotherapy to liver cancer patients before they received surgery and found that tumours died off significantly before surgery in a third of the patients, according to results reported in The Lancet Gastroenterology and Hepatology.   The results  The researchers believe that the neoadjuvant immunotherapy—therapy given before surgery—not only may kill the tumour prior […]

Researchers at the Francis Crick Institute and Universidade de Santiago de Compostela have identified how the hepatitis B virus (HBV) can support the survival and growth of liver cancer, with this process starting early in tumour development, in some instances up to 20 years before cancer diagnosis.  Context  Around 240 million people around the world are infected with HBV. […]

More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances in 3D culture, we and others have demonstrated the […]

More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. This app note offers insight and media for drug discovery.  While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances […]

Calliditas Therapeutics has been granted Fast Track designation by the US Food and Drug Administration (FDA) for its NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis (PBC). Setanaxib has previously been granted orphan drug designation for PBC in the US and Europe. “We are delighted […]